Effect of β3-adrenergic receptor agonists on [18F] fluorodeoxyglucose uptake in brown adipose tissues in positron emission tomography images of elderly patients.
IF 3.1 3区 医学Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
John Kenneth V Gacula, Kenichiro Ogane, Kaori Fuse, Miyako Morooka Chikanishi, Kimiteru Ito
{"title":"Effect of β3-adrenergic receptor agonists on [<sup>18</sup>F] fluorodeoxyglucose uptake in brown adipose tissues in positron emission tomography images of elderly patients.","authors":"John Kenneth V Gacula, Kenichiro Ogane, Kaori Fuse, Miyako Morooka Chikanishi, Kimiteru Ito","doi":"10.1186/s13550-025-01286-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Brown adipose tissues (BAT) are highly vascularized, mitochondria-rich tissues involved in thermogenesis. Physiological [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) uptake in BAT can be influenced by several factors, including the use of medications that act on β-adrenergic receptors. Recently, increased [<sup>18</sup>F]FDG BAT uptake has been observed in elderly patients (≥ 60 years old) receiving β3-adrenergic receptor agonists. With the increasing use of β3-adrenergic receptor agonists for managing overactive bladder, there is limited understanding of their potential association with increased [<sup>18</sup>F]FDG BAT uptake. This study retrospectively investigated whether treatment with β3-adrenergic receptor agonists is associated with increased [<sup>18</sup>F]FDG BAT uptake among elderly patients. [<sup>18</sup>F]FDG positron emission tomography (PET) images were analyzed visually and through SUVmax measurements across eight predefined regions of interest (ROI): cervical, periclavicular, axillary, mediastinal, paravertebral, paraabdominal aortic, perirenal, and perisplenic regions. Patients' medication history and clinical records were reviewed to assess β3-adrenergic receptor agonist use relative to their [<sup>18</sup>F]FDG PET study.</p><p><strong>Results: </strong>Forty-four elderly patients, each with a single [<sup>18</sup>F]FDG PET scan, were included in the analysis. Among the eight ROIs, the perirenal region showed a statistically significant increase in [<sup>18</sup>F]FDG BAT uptake in patients receiving β3-adrenergic receptor agonists compared with those not receiving, based on both visual analysis (p < 0.001) and SUVmax measurements (p = 0.030). All patients receiving β3-adrenergic receptor agonists demonstrated increased [<sup>18</sup>F]FDG BAT uptake in the paravertebral region.</p><p><strong>Conclusion: </strong>In patients aged ≥ 60 years, β3-adrenergic receptor agonist therapy appears to be associated with increased [<sup>18</sup>F]FDG BAT uptake, particularly in the perirenal area.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"101"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12321703/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01286-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Brown adipose tissues (BAT) are highly vascularized, mitochondria-rich tissues involved in thermogenesis. Physiological [18F]fluorodeoxyglucose ([18F]FDG) uptake in BAT can be influenced by several factors, including the use of medications that act on β-adrenergic receptors. Recently, increased [18F]FDG BAT uptake has been observed in elderly patients (≥ 60 years old) receiving β3-adrenergic receptor agonists. With the increasing use of β3-adrenergic receptor agonists for managing overactive bladder, there is limited understanding of their potential association with increased [18F]FDG BAT uptake. This study retrospectively investigated whether treatment with β3-adrenergic receptor agonists is associated with increased [18F]FDG BAT uptake among elderly patients. [18F]FDG positron emission tomography (PET) images were analyzed visually and through SUVmax measurements across eight predefined regions of interest (ROI): cervical, periclavicular, axillary, mediastinal, paravertebral, paraabdominal aortic, perirenal, and perisplenic regions. Patients' medication history and clinical records were reviewed to assess β3-adrenergic receptor agonist use relative to their [18F]FDG PET study.
Results: Forty-four elderly patients, each with a single [18F]FDG PET scan, were included in the analysis. Among the eight ROIs, the perirenal region showed a statistically significant increase in [18F]FDG BAT uptake in patients receiving β3-adrenergic receptor agonists compared with those not receiving, based on both visual analysis (p < 0.001) and SUVmax measurements (p = 0.030). All patients receiving β3-adrenergic receptor agonists demonstrated increased [18F]FDG BAT uptake in the paravertebral region.
Conclusion: In patients aged ≥ 60 years, β3-adrenergic receptor agonist therapy appears to be associated with increased [18F]FDG BAT uptake, particularly in the perirenal area.
EJNMMI ResearchRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍:
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.